Background: Desmoid tumors are rare locally invasive, benign neoplasms that develop along aponeurotic structures. Current treatment is complicated by associated morbidity and high recurrence rates. Methods: A retrospective, single-institution review identified 23 patients (age: 16-77) with extra-abdominal desmoid tumors who received CT-guided percutaneous cryoablation as either a first-line (61%) or salvage (39%) treatment in 30 sessions between 2014 and 2018. Median maximal lesion diameter was 69 mm (range: 11-209). Intent was curative in 52% and palliative in 48%. Contrast-enhanced cross-sectional imaging was obtained before and after treatment in addition to routine clinical follow-up. Results: Technical success was achieved in all patients. The median follow-up was 15.4 months (3.5-43.4). Symptomatic improvement was demonstrated in 89% of patients. At 12 months, the average change in viable volume was −80% (range −100% to + 10%) and response by modified response evaluation criteria in solid tumors (mRECIST) was CR 36%, PR 36%, and SD 28% No rapid postablation growth or track seeding was observed. Four patients underwent repeat cryoablation for either residual or recurrent disease. Two patients sustained a major procedural complication consisting of significant neuropraxia. Conclusion: Cryoablation for desmoid tumors demonstrates a high degree of symptom improvement and local tumor control on early follow-up imaging with relatively low morbidity.
destructive, with the potential to threaten limb and occasionally life.
As a result, these tumors have long challenged specialists to devise a treatment paradigm that will cause the least harm.
Desmoid tumors typically arise from mutations in the adenomatous polyposis coli (APC) or CTNNB1 genes, both of which are fundamental components of the wingless/Integrated signaling pathway that regulates turnover and degradation of β-catenin. Mutations along this pathway result in inhibition of β-catenin degradation, leading to its accumulation in the cytoplasm and the nucleus of affected cells. The majority of cases, reportedly 85% to 93%, arise sporadically from β-catenin-activation mutations in the CTNNB1 gene. 1 Sporadic cases have a predilection for female patients (2:1).
The age at diagnosis can be variable, although typically peaks at 25 to 35. 2 Desmoid tumors can develop throughout the body. Intraabdominal desmoids are more often related to familial APC gene mutations associated with familial adenomatous polyposis (FAP), and management frequently differs from that of extra-abdominal desmoid tumors. Extra-abdominal disease is most commonly located in the limb or limb girdle (50%), trunk (43%), or head and neck (7%). 3 Desmoid tumor occurrence has also been associated with pregnancy, trauma, and surgery.
NCCN guidelines currently recommend the use of surgical resection, radiation, systemic therapy, and observation for the treatment of both primary and recurrent desmoid tumors. Although wide local excision has served as the gold standard treatment for desmoid tumors in the past, no individual study or meta-analysis has proven that surgical resection yields superior outcomes over other modalities. 4 While resection can be effective in achieving local control, notable disadvantages include a high long-term recurrence rate of up to 40%, 4 destruction of native tissue planes, neurovascular injury, potential activation of residual tumor along dissection planes, and duration of postoperative recovery.
Active surveillance can be a reasonable treatment option in lieu of targeted local therapy for many lesions, as several large, multiinstitutional studies 3, 5, 6 have demonstrated spontaneous regression rates of 28% to 50% in recent years. However, identifying these lesions prospectively can be difficult even when accounting for features with high risk for progression, which include large tumor size, young age, and extremity site tumors. 3, 7 Surveillance as a firstline therapy may be contraindicated for patients who are symptomatic or for lesions where further growth would alter future treatment options or lead to functional limitations.
The dual possibility of spontaneous regression and high postoperative recurrence rates has led to a paradigm shift where nonsurgical therapies are often pursued before attempting surgical resection. In this context, percutaneous cryoablation has been explored as a less invasive option for local control and potential cure of desmoid tumors with promising early results. 8 Cryoablation causes direct injury to cellular membranes and vascular endothelium through the alternating formation and thawing of intracellular ice. 9 Collectively, these processes result in immediate apoptosis at the epicenter of the ablation zone and vascular thrombosis leading to additional ischemic injury. Uniquely, connective tissue structure is often preserved with this ablative therapy. Interestingly, despite many centers migrating toward cryoablation as an alternative treatment option for these patients, outcome studies are limited, and there is currently no mention of ablative therapies in the NCCN treatment algorithm for desmoid tumors. 10 Our study presents the largest, most heterogeneous cohort of patients treated with cryoablation to date. While several smaller series have previously described institutional experience in the treatment of extra-abdominal desmoid tumors, 11, 12 most patients in these studies were treated with cryoablation only after previous treatment failure or for inoperable lesions. The purpose of this study is to evaluate the efficacy, safety, and unique advantages of cryoablation for both first-line and salvage treatment of extraabdominal desmoid tumors.
| MATERIALS AND METHODS

| Patient selection
After gaining institutional review board approval, a retrospective search of our single-institution database was performed to identify patients with biopsy-proven desmoid tumors who were treated with percutaneous cryoablation from July 2014 to May 2018, with followup through January 2019. Patients were discussed at our multidisciplinary tumor board and all treatment options were considered before proceeding with cryoablation.
| Data collection and analysis
Data collection was performed through a retrospective chart review and managed using the Research Electronic Data Capture database. 13 Variables recorded for analysis included demographic information, previous treatment modalities, adjunctive therapy, imaging parameters, symptom characteristics, and complications. Our standardized ablation protocol consisted of two consecutive cycles using a 10-minute freeze followed by a 5-minute passive thaw, which is frequently used in other solid organ ablations. 15 Modifications such as decreased freeze time or decreased energy were used at the discretion of the treating physician if there was imaging or neurologic evidence that the ablation zone was encroaching upon a critical structure. Periodic CT and ultrasound imaging were performed during ablation to ensure that nontarget structures were safely protected from the ablation zone. A noncontrast CT was obtained at the end of the final freeze cycle to define the maximum ablation zone, to identify any untreated area of the mass, and to verify there was no visible injury to surrounding structures. After a routine postprocedural monitoring period, patients were either discharged home on the same day or admitted overnight for observation, depending on the complexity of the procedure and the patientʼs medical comorbidities.
| RESULTS
During the study period, 23 individual patients (61% female, 39% male) presenting with a single desmoid lesion were treated with cryoablation ( Table 1 ). The median patient age at the time of the procedure was 40.5 years (range: 16-77). One patient had FAP. F I G U R E 1 (A) Pre-ablation axial T1 postcontrast MRI and (B) procedural images obtained for a patient undergoing cryoablation of an upper extremity desmoid tumor. Sequential axial noncontrast CT images obtained intermittently throughout the procedure reveal a progressive increase in the ablation zone that ultimately encompasses the mass. (C) First follow-up axial T1 (fat sat.) postcontrast MRI revealing a small area of residual enhancing tumor at the posterior ablation margin, which was treated with a second cryoablation procedure, with extensive heterogenous enhancement anteriorly consistent with expected posttreatment change. MRI, magnetic resonance imaging Thirty cryoablation procedures were performed in these 23 patients (Table 2) . Cryoablation was performed with a goal of complete A0 ablation in 12 patients (52%), with an A0 ablation confirmed on followup imaging in 5 patients and presumed based on intra-procedural imaging in 1 patient ( Figure 2 ). For the remaining 11 patients (48%), the decision was made preoperatively not to attempt complete ablation due to either lesion complexity or proximity to critical structures, in which case treatment was performed for palliative symptom control. Four patients underwent a second ablation procedure for the treatment of Tumor development in the scar tissue of a previous, unrelated surgical procedure 2 1 3
Antecedent trauma in the region of the first-line tumor 3 1 4
Abbreviations: LD, longest cross-sectional dimension; NSAIDs, non-steroidal anti-inflammatories; SERM, selective estrogen receptor modulator; TKI: tyrosine kinase inhibitor.
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Two procedures (6.7%, 2 of 30) resulted in major complications according to the SIR Adverse Event Classification Guidelines, both significant neuropraxia (Table 3) . One patient experienced deltoid weakness after ablation of a neck lesion that resolved after 6 months.
A second patient experienced a foot drop from sciatic nerve injury with a near-total resolution at 9 months. Four additional procedures (13.3%, 4 of 30) resulted in minor complications.
| DISCUSSION
The current dataset is one of the largest reported utilizing cryoablation in the treatment of desmoid tumors, and the first cohort with a majority of patients receiving cryoablation as first-line therapy.
Primarily, our study demonstrates the ability of cryoablation to achieve a very high rate of symptom improvement. The 90% clinical response rate of this study is even more significant when considering over two-thirds of patients received only partial ablations, suggesting that complete tumor ablation is not necessary to achieve significant improvement in clinical symptoms and that partial ablation can be offered with confidence.
Moreover, we achieved a very high rate of local disease control. Note: Additional follow-up after third ablation is pending. Abbreviations: LD, longest cross-sectional dimension; S, sulindac; SERM, selective estrogen receptor modulator; SR, surgical resection; TKI, tyrosine kinase inhibitor; XRT, radiation therapy. 1 Based on intra-procedural imaging, post-procedure contrast-enhanced magnetic resonance imaging not available. 2 Performed as 2 staged procedures, A2a ablation at the completion of the second stage. 3 Performed as 3 staged procedures, A2b ablation at the completion of the second stage.
nine tumors (39%) had a follow-up of 12 months or more. Two notable differences can be observed between our cohorts. First, in their experience, only two patients received cryoablation as first-line therapy, with the remaining patients having failed one or more prior treatment modalities. Second, their series was more homogeneous in comparison to our patient cohort, as it included a large percentage of paraspinal tumors, which were not well-represented in our cohort.
Given that tumor location can be a prognostic indicator of behavior, this difference may account for some degree of variability between the two studies, particularly with regard to disease recurrence and progression if incompletely treated. The absence of recurrent disease after complete A0 ablation on follow-up imaging at 1 year is promising, especially when viewed in the context of a 23% recurrence rate at 2 years following an R0 surgical resection. 4 Longer term follow-up is needed to assess how A0 cryoablation compares to the R0 5-year recurrence rate of almost 40%. 4 Radiation therapy has been shown to provide benefit in cases of definitive therapy, adjuvant therapy following surgical resection, and retreatment in cases of recurrence. 16, 17 A recent Phase II trial of 44 patients receiving 56 Gy in 28 fractions for primary and recurrent 14%, PR 36%, SD 41%, and PD 7% by RECIST criteria, similar to the results of the current study despite differences in assessment. 18 Several small studies investigating systemic therapy have shown moderate benefit with NSAIDs, antiestrogen therapy, and cytotoxic chemotherapy with widely variable rates of partial imaging response in the ranges of 15% to 50%. 19, 20 More recently, tyrosine kinase inhibitors have been evaluated with moderate effect as well with imaging response rates of 5% to 20% at 1 year and a larger majority exhibiting progression-free disease between 60% and 70%. 21, 22 In six patients, a curative A0 ablation was attempted, but unfortunately not initially achieved. For some lesions, it can be quite challenging to ensure the ablation zone completely covers the tumor.
A major reason for this is poor tumor visibility during ablation due to the minimal attenuation difference between tumor and surrounding muscle on the unenhanced CT imaging used during a cryoablation procedure, especially in lesions that are large with invasive or multifocal morphologies. Advanced imaging techniques such as the fusion of preoperative contrast-enhanced imaging with intra-procedural imaging (either ultrasound, CT, or magnetic resonance) and the placement of ablation probes using needle guidance and ablation planning software can minimize this. Significant improvements in these workflows will be necessary before adoption is widespread;
however, we believe the rate of unintentional, incomplete ablations will continue to shrink as these advanced imaging technologies mature and become more efficient and user-friendly in the future.
Several features of cryoablation provide a distinct advantage over alternative treatment options. Unlike surgical resection, cryoablation generally preserves connective tissue planes. As a result, delayed recurrence after ablation is usually in the same Our low rate of procedural complications compares favorably to surgical and radiation therapy complication rates. 19 The heterogeneity of our dataset underscores the unique risk profile of cryoablation for desmoid tumors. In our experience, the most common structures at risk for injury during cryoablation of extraabdominal desmoid tumors include the skin, bowel, and adjacent nerves. In some cases, we have utilized intraoperative neurologic monitoring with motor and somatosensory evoked potentials to provide real-time feedback regarding nerve function during ablation.
While we have found these techniques helpful, the accuracy of neurologic monitoring feedback can be limited by many intraprocedural parameters, most notably type of anesthesia. In our study, we experienced two major procedural complications (7%) that were both nerve injuries, one despite neurologic monitoring. The targeted tumors were in close proximity to or invading adjacent neurologic structures. In both cases, the injury occurred in part due to a small margin of error and difficult visualization of the nerve on unenhanced CT imaging with some degree of image degradation from the metallic ablation probes.
Our study has several limitations as a small, retrospective series with variable follow-up times. It is important to highlight that the current patient cohort is heterogenous and comprised of several distinct patient groups which should be considered somewhat separately. A key distinction is between the subset in which a complete A0 ablation with an intent to cure can be performed safely and the subset in which it cannot, usually due to pre-existing proximity to or invasion of critical structures, most often nerves, which would carry unacceptable morbidity if injured. In these cases, only partial ablation was performed with the intent to debulk the tumor mass for palliative symptom control, which inherently biases the collective imaging response of the cohort. Notably, our series did not include any patients with intra-abdominal desmoid lesions, which are typically are more aggressive, more difficult to treat with ablation, and more prone to recurrence.
| CONCLUSION
In summary, cryoablation should be considered safe and effective as both a first-line and salvage treatment option for desmoid tumors requiring local disease control. While early recurrence rates are favorable, additional long-term follow-up will be essential in determining whether disease control rates compare favorably with current standards of care in this very persistent disease. However, cryoablation offers many advantages over therapies currently recommended by national guidelines as a minimally-invasive, singlesession, and repeatable procedure with low morbidity and swift recovery times.
As in many sarcoma centers worldwide, our institutional treatment paradigm has changed over the last several years. If decided by our multidisciplinary tumor board that treatment is preferable to active surveillance, cryoablation is often used in both first-line and salvage situations, while reserving systemic therapy and radiation therapy for the adjunct setting in cases with residual or recurrent disease that cannot be safely ablated. Surgery is generally reserved for intra-abdominal lesions unresponsive to alternative therapies.
While clinical trials evaluating cryoablation of desmoid tumors are ongoing outside of the United States, they currently do not address its use as a first-line treatment modality, but rather as a means of salvage therapy. 24 We believe that this study provides sufficient evidence to support a prospective clinical trial with longterm follow-up evaluating cryoablation as first-line therapy for patients that would benefit from local tumor control.
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